Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.

Tregellas JR, Tanabe J, Rojas DC, Shatti S, Olincy A, Johnson L, Martin LF, Soti F, Kem WR, Leonard S, Freedman R.

Biol Psychiatry. 2011 Jan 1;69(1):7-11. doi: 10.1016/j.biopsych.2010.07.004. Epub 2010 Aug 21.

2.

Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia.

Tregellas JR, Olincy A, Johnson L, Tanabe J, Shatti S, Martin LF, Singel D, Du YP, Soti F, Kem WR, Freedman R.

Neuropsychopharmacology. 2010 Mar;35(4):938-42. doi: 10.1038/npp.2009.196. Epub 2009 Dec 2.

3.

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.

Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R.

Arch Gen Psychiatry. 2006 Jun;63(6):630-8.

PMID:
16754836
4.

Initial phase 2 trial of a nicotinic agonist in schizophrenia.

Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman-Bonilla A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F, Kem WR.

Am J Psychiatry. 2008 Aug;165(8):1040-7. doi: 10.1176/appi.ajp.2008.07071135. Epub 2008 Apr 1.

5.

α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.

Freedman R.

Annu Rev Med. 2014;65:245-61. doi: 10.1146/annurev-med-092112-142937. Epub 2013 Oct 9. Review.

PMID:
24111888
6.

Intragastric DMXB-A, an alpha7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice.

Simosky JK, Stevens KE, Kem WR, Freedman R.

Biol Psychiatry. 2001 Oct 1;50(7):493-500.

PMID:
11600102
7.

A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.

Buccafusco JJ, Terry AV Jr.

Biochem Pharmacol. 2009 Oct 1;78(7):852-62. doi: 10.1016/j.bcp.2009.06.102. Epub 2009 Jul 3.

8.

DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats.

O'Neill HC, Rieger K, Kem WR, Stevens KE.

Psychopharmacology (Berl). 2003 Sep;169(3-4):332-9. Epub 2003 May 21.

PMID:
12759805
9.

Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Olincy A, Freedman R.

Handb Exp Pharmacol. 2012;(213):211-32. doi: 10.1007/978-3-642-25758-2_8. Review.

10.

DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid(25-35(-) ) injected mice through preventing the dysfunction of alpha7 nicotinic receptor.

Chen L, Wang H, Zhang Z, Li Z, He D, Sokabe M, Chen L.

J Neurosci Res. 2010 Jun;88(8):1784-94. doi: 10.1002/jnr.22345.

PMID:
20127813
11.
12.

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Martin LF, Kem WR, Freedman R.

Psychopharmacology (Berl). 2004 Jun;174(1):54-64. Epub 2004 Feb 19. Review.

PMID:
15205879
15.

Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Olincy A, Stevens KE.

Biochem Pharmacol. 2007 Oct 15;74(8):1192-201. Epub 2007 Jul 17. Review.

16.

The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys.

Cannon CE, Puri V, Vivian JA, Egbertson MS, Eddins D, Uslaner JM.

Neuropharmacology. 2013 Jan;64:191-6. doi: 10.1016/j.neuropharm.2012.05.003. Epub 2012 May 29.

PMID:
22659472
18.

Schizophrenia and the alpha7 nicotinic acetylcholine receptor.

Martin LF, Freedman R.

Int Rev Neurobiol. 2007;78:225-46. Review.

PMID:
17349863
19.

Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.

Zhang XY, Liu L, Liu S, Hong X, Chen da C, Xiu MH, Yang FD, Zhang Z, Zhang X, Kosten TA, Kosten TR.

Am J Psychiatry. 2012 Sep;169(9):974-81. doi: 10.1176/appi.ajp.2012.11081289.

PMID:
22952075
20.

Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.

Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C, Zanelli U, Ghiron C, Haydar S, Dunlop J, Terstappen GC.

J Pharmacol Exp Ther. 2009 May;329(2):459-68. doi: 10.1124/jpet.108.150094. Epub 2009 Feb 17.

Items per page

Supplemental Content

Write to the Help Desk